Page 1 of 10 Docket #1257 Date Filed: 01/21/2025 Case 18-10518-JTD Doc 1257 Filed 01/21/25

UNITED STATES BANKRUPTCY COURT

FOR	THE DISTRICT OF	<u>DELAWARE</u>
In re: Orexigen Therapeutics, Inc.	\$ \$ ——————————————————————————————————	Case No. <u>18-10518</u>
Debtor(s)	§ §	☐ Jointly Administered
Post-confirmation Report		Chapter 11
Quarter Ending Date: 12/31/2024	_	Petition Date: <u>03/12/2018</u>
Plan Confirmed Date: 05/17/2019	_	Plan Effective Date: 05/31/2019
This Post-confirmation Report relates to: Re		ntity: Wind-Down Administrator
O 5.	ner riadionized rancy of En	Name of Authorized Party or Entity
s/ Levi Akkerman	Lev	vi Akkerman

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.

Printed Name of Responsible Party

Potter Anderson & Corroon LLP

1313 N. Market St., 6th Floor, Wilmington, DE 19801-6108

Address



Signature of Responsible Party

01/21/2025

Date

Case No. 18-10518

Part 1: Summary of Post-confirmation Transfers

	Current Quarter	Total Since Effective Date
a. Total cash disbursements	\$10,708	\$10,995,541
b. Non-cash securities transferred	\$0	\$0
c. Other non-cash property transferred	\$0	\$0
d. Total transferred (a+b+c)	\$10,708	\$10,995,541

			Approved Current Quarter	Approved Cumulative	Paid Current Quarter	Paid Cumulati
Profess incurre	Professional fees & expenses (bankruptcy) incurred by or on behalf of the debtor Aggregate Total		\$0	\$100,985	\$0	\$100
Itemize	ed Breakdown by Firm					
	Firm Name	Role				
i	Potter Anderson & Corroon LL	Special Counsel	\$0	\$16,280	\$0	\$16
ii	Quinn Emanuel Urquhart & Sul	Special Counsel	\$0	\$84,705	\$0	\$84
iii						
iv						
v						
vi						
vii						
viii						
ix						
x						
xi						
xii						
xiii						
xiv						
xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						

xxx				
xxxi				
xxxii				
xxxiii				
xxxiv				
xxxv				
xxxvi				
xxxvii				
xxxvii				
xxxix				
xl				
xli				
xlii				
xliii				
xliv				
xlv				
xlvi				
xlvii				
xlviii				
xlix				
1				
li				
lii				
liii				
liv				
lv				
lvi				
lvii				
lviii				
lix				
1x				
lxi				
lxii				
lxiii				
lxiv				
lxv				
lxvi				
lxvii				
lxviii				
lxix				
lxx				
lxxi				
	<u> </u>		l	

Case 18-10518-JTD Doc 1257 Filed 01/21/25 Page 4 of 10

Debtor's Name Orexigen Therapeutics, Inc.

Case No. 18-10518

Exxii				
Dari Dari	lxxii			
	lxxiii			
	lxxiv			
	lxxv			
	lxxvi			
Ixxx	lxxvii			
Ixxxi	lxxviii			
	lxxix			
Ixxxii	lxxx			
Ixxxiv	lxxxi			
Ixxxv	lxxxii			
Ixxxvi	lxxxiii			
lxxxvi	lxxxiv			
lxxxvi	lxxxv			
lxxxvi	lxxxvi			
lxxxix	lxxxvi			
xc xci xcii xciii xciii xciv xcv xcv xcvi xcvi	lxxxvi			
xci xcii xciii xciv xcv xcvi xcvii	lxxxix			
xcii xciii xciv xcv xcvi xcvii	xc			
xciii xciv xcv xcv xcvii	xci			
xciv xcv xcvi xcvii	xcii			
xcvi xcvii	xciii			
xcvi xcvii	xciv			
xcvii	xcv			
	xcvi			
	xcvii			
XCVIII	xcviii			
xcix	xcix			
С	С			
ci	ci			

				Approved	Approved	Paid Current	Paid
				Current Quarter	Cumulative	Quarter	Cumulative
b.		sional fees & expenses (nor d by or on behalf of the de) Aggregate Total	\$0	\$0	\$0	\$0
	Itemize	ed Breakdown by Firm					
		Firm Name	Role				
	i	N/A		\$0	\$0	\$0	\$0
	ii						
	iii						
	iv						
	v						
	vi						

vii			
viii			
ix			
x			
xi			
xii			
xiii			
xiv			
xv			
xvi			
xvii			
xviii			
xix			
xx			
xxi			
xxii			
xxiii			
xxiv			
xxv			
xxvi			
xxvii			
xxviii			
xxix			
xxx			
xxxi			
xxxii			
xxxiii			
xxxiv			
xxxv			
xxxvi			
xxxvii			
xxxvii			
xxxix			
xl			
xli			
xlii			
xliii			
xliv			
xlv			
xlvi			
xlvii			
xlviii			
AIVIII			

			1	1	
X	lix				
1					
li					
li					
li	iii				
li	iv				
lv	V				
lv	vi				
lv	vii				
lv	viii				
li	ix				
15	X				
15	xi				
15	xii				
15	xiii				
lx	xiv				
15	XV				
13	xvi				
15	xvii				
15	xviii				
15	xix				
15	XX				
15	xxi				
15	xxii				
lx	xxiii				
15	xxiv				
	XXV				
15	xxvi				
15	xxvii				
12	xxviii				
12	xxix				
15	XXX				
15	xxxi				
15	xxxii				
15	xxxiii				
12	xxxiv				
-	XXXV				
-	xxxvi				
-	xxxvi				
-	xxxvi				
<u> </u>	xxxix				
-	С				

Case 18-10518-JTD Doc 1257 Filed 01/21/25 Page 7 of 10

Debto	or's Name Orexigen Therapeution	cs, Inc.				Case No. 18-105	18
	xci						
	xcii						
	xciii						
	xciv						
	XCV						
	xcvi						
	xcvii						
	xcviii						
	xcix						
	c						
	ci						
c.	All professional fees and ex	nenses (debtor & commit	ttees)	\$0	\$100,9	35 \$0	\$100,98
<u> </u>	Tim professionar rees and ex	penses (dector & commi	itees)	ΨΟ	Ψ100,	55 \$6	Ψ100,50
Part 3	3: Recoveries of the Holders of	f Claims and Interests u	nder Confirmed Pla	n			
		Total Anticipated Payments Under Plan	Paid Current Quarter	Paid C	umulative	Allowed Claims	% Paid of Allowed Claims
a. A	dministrative claims	\$0	\$0		\$0	\$192,468	0%
b. S	ecured claims	\$1,162,758	\$0		\$8,537,068	\$165,000,000	5%
c. P	riority claims	\$90,795	\$0		\$90,795	\$90,795	100%
d. G	General unsecured claims	\$474,814	\$0		\$646,134	\$93,109,625	1%
	quity interests	\$0	\$0		\$0		

Post A. Occasionalism			
Part 4: Questionnaire			
a. Is this a final report?		Yes No •	
If yes, give date Final Decree was entered:			
If no, give date when the application for Final Decree is anticipated:	12/31/2025		
h Are you current with quarterly IIS Trustee fees as set forth under 28 IIS C &	10302	Ves No	

Case 18-10518-JTD Doc 1257 Filed 01/21/25 Page 8 of 10

Debtor's Name Orexigen Therapeutics, Inc.


Case No. 18-10518

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information and provision of this information is mandatory. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6) and to otherwise evaluate whether a reorganized chapter 11 debtor is performing as anticipated under a confirmed plan. Disclosure of this information may be to a bankruptcy trustee when the information is needed to perform the trustee's duties, or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." *See* 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case, or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Post-confirmation Report and its attachments, if any, are true and correct and that I have been authorized to sign this report.

/s/ Peter Kravitz	Peter Kravitz
Signature of Responsible Party	Printed Name of Responsible Party
Wind Down Administrator	01/21/2025
Title	Date




Page 1


Other Page 1

Page 2 Minus Tables


Bankruptcy Table 1-50




Bankruptcy Table 51-100



Non-Bankruptcy Table 1-5(



Non-Bankruptcy Table 51-100



Part 3, Part 4, Last Page

In re *Orexigen Therapeutics, Inc.*Case No. 18-10518 (JTD)

Notes to Post-Confirmation Report for the Quarter Ended December 31, 2024

Part 2b

The Wind Down Administrator has not made any payments on account of pre-confirmation professional fees and expenses.

Part 3

"Total Anticipated Payments Under Plan" reflects amounts paid plus cash on hand as of the date of this report, and is subject to reduction based on, among other things, operating expenses of the Wind Down Administrator and/or the estates.

CERTIFICATE OF SERVICE

I, Levi Akkerman, do hereby certify that on January 21, 2025, a copy of the foregoing

Chapter 11 Post-Confirmation Report for the Quarter Ending 12/31/2024 was served on the

parties listed below in the manner indicated.

Richard L. Schepacarter, Esq.
Office of the United States Trustee
844 King Street, Room 2207
Lockbox 35
Wilmington, Delaware 19801

Email: richard.schepacarter@usdoj.gov

Via Email

Timothy Jay Fox, Jr.
Office of the United States Trustee
844 King Street, Room 2207
Lockbox 35
Wilmington, Delaware 19801
Email: timothy.fox@usdoj.gov

Via Email

/s/ Levi Akkerman
Levi Akkerman (No. 7015)